Endogenous Levels, Detection Time, and Symptoms of Gamma‐Hydroxybutyric Acid: Results From a Placebo‐Controlled Clinical Trial
Basic & Clinical Pharmacology & Toxicology · 2025-12 · 137 (6)
DOI: 10.1111/bcpt.70133 ↗At a glance
Randomisierte kontrollierte Studie in Basic & Clinical Pharmacology & Toxicology, published online on 2025-11-08. Written by Kathrine Bohn Faldborg and 3 co-authors. Institution: Department of Forensic Medicine, Aarhus University, Aarhus, Denmark. Major MEDLINE topics: Sodium Oxybate, Hydroxybutyrates, Substance Abuse Detection. Cited 2 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: The Council of the Danish Victims Fund.
Abstract (original language)
Gamma‐hydroxybutyric acid (GHB), a potential agent in drug‐facilitated sexual assault, is difficult to detect due to rapid elimination, endogenous presence, and possible postsampling formation. We conducted a randomised, placebo‐controlled trial in 30 healthy volunteers, administering 50‐mg/kg sodium oxybate or placebo, to investigate symptoms, pharmacokinetics and endogenous concentrations. Blood was collected in fluoride‐oxalate (FX) tubes, and urine and oral fluid in additive‐free tubes, at baseline, 1, 2, 3, 4, 6, 12, and 24 (urine only) hours post‐administration. Samples were immediately cooled, stored at −70°C, and analysed using LC–MS/MS. Maximal endogenous GHB concentrations were 0.050 μg/mL in blood, 0.41 μg/mL in urine, and 0.93 μg/mL in oral fluid. GHB‐treated participants reported vertigo and fatigue, with no significant memory impairment. Median peak GHB concentrations post‐administration were 50, 440, and 29 μg/mL in blood, urine, and oral fluid, respectively. Oral fluid appeared unsuitable for GHB detection. As endogenous concentrations in blood did not exceed 0.050 μg/mL, a theoretical cut‐off with a safety margin (0.25 μg/mL) would yield a negligible risk of false positives in samples collected in FX tubes and cooled immediately. Applying this cut‐off extended the blood detection window ≥ 2 h in all GHB‐treated participants, surpassing that in urine at a 6‐μg/mL cut‐off.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Forensic Medicine, Aarhus University, Aarhus, Denmark.
- Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark.
ORCID profiles: Kathrine Bohn Faldborg, Lambert Kristiansen Sørensen, Jørgen Bo Hasselstrøm, Charlotte Uggerhøj Andersen
Funding
- The Council of the Danish Victims Fund
Cite
APA
Faldborg, K. B., Sørensen, L. K., Hasselstrøm, J. B., & Andersen, C. U. (2025). Endogenous Levels, Detection Time, and Symptoms of Gamma‐Hydroxybutyric Acid: Results From a Placebo‐Controlled Clinical Trial. Basic & Clinical Pharmacology & Toxicology, 137(6). https://doi.org/10.1111/bcpt.70133
Vancouver
Faldborg KB, Sørensen LK, Hasselstrøm JB, Andersen CU. Endogenous Levels, Detection Time, and Symptoms of Gamma‐Hydroxybutyric Acid: Results From a Placebo‐Controlled Clinical Trial. Basic & Clinical Pharmacology & Toxicology. 2025;137(6). doi:10.1111/bcpt.70133
BibTeX
@article{Faldborg2025,
author = {Faldborg, Kathrine Bohn and Sørensen, Lambert Kristiansen and Hasselstrøm, Jørgen Bo and Andersen, Charlotte Uggerhøj},
title = {Endogenous Levels, Detection Time, and Symptoms of Gamma‐Hydroxybutyric Acid: Results From a Placebo‐Controlled Clinical Trial},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
volume = {137},
number = {6},
doi = {10.1111/bcpt.70133}
}
EUVIMED